This post has been archived and contains information that may be out of date.
On Jan. 5, the Centers for Disease Control and Prevention (CDC) endorsed the recommendation made earlier that day by its Advisory Committee on Immunization Practices that eligibility for a single booster dose of the Pfizer-BioNTech vaccine be expanded to ages 12-15.
This CDC move follows the Jan. 3 action by the Food and Drug Administration expanding the emergency use authorization for a Pfizer-BioNTech COVID-19 booster for those in this age group. With this latest action, the CDC now recommends that ages 12-17 receive a booster shot five months after their initial Pfizer-BioNTech vaccine series.
At this time, only the Pfizer-BioNTech COVID-19 vaccine is authorized and recommended for ages 12-17.
